摘要
自20世纪70年代初，哈尔滨医科大学第一附属医院开始尝试用砷剂（As2O3）治疗急性早幼粒细胞白血病（APL），并取得良好效果，自此As203的抗肿瘤效应成为了研究热点。近年来，不断有研究表明GSH在决定肿瘤细胞对化疗药物敏感性方面起着重要作用，对As203敏感的肿瘤细胞比耐药肿瘤细胞的GSH含量低，而抗坏血酸（AA）可降低细胞内GSH水平。据此，一些学者为了提高As203的抗肿瘤疗效，减少其应用剂量，提出了以AA与As2O3联合应用为基础的新型治疗方案，并在一些肿瘤的基础实验和临床研究中取得了一定成效。因此，本文中我们主要就该方案在不同肿瘤中应用的最新研究进展加以综述，并展望As203联合AA在抗肿瘤治疗中的应用价值和前景，为进一步研究和探寻更合理的化疗方案提供参考。
Since 1970s,a Chinese study group at Harbin Medical University First Hospital began to use arsenic trioxide（ As203 ） treatment of acute promyelocytic leukemia（APL） and achieved good results. Anticaneer effect of As203 has become a research hotspot. In recent years, a growing number of studies demonstrate that glutathione（GSH） plays a central role in the delicate balance in determining sensitivity towards apoptosis or resistance of tumor cells. Cancer cells sensitive to As203 may contain less GSH than resistant cancer cells, and ascorbic acid （AA） can reduce the level of intracellular GSH. To improve anticancer effect of As203 and reduce its application dose,some scholars have proposed a new type of treatment program that As203 combination with AA for cancer treatment. In some basic experimental and clinical cancer research, As203 combination with AA has achieved some success. In light of this dosage regimen for the different tumors in the latest research progress, we conducted a review in this paper, which may be helpful for further exploring more reasonable chemotherapy regimens.
出处
《实用肿瘤学杂志》
CAS
2012年第3期262-267,共6页
Practical Oncology Journal
基金
黑龙江省科技攻关课题（GC09C407-5）
